{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:54:30Z","timestamp":1774659270796,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Seoul National University Hospital (SNUH) Research Fund.","award":["0320200180"],"award-info":[{"award-number":["0320200180"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The current COVID-19 pandemic has highlighted the urgent need to develop effective therapeutic strategies. We evaluated the in vitro antiviral effect against SARS-CoV-2 of a hepatitis B virus (HBV) hexamer peptide, Poly6, which is capable of eliciting an antiviral effect against human immunodeficiency virus -1 (HIV-1), as a novel HIV-1 integrase inhibitor, and a strong anticancer immune response in an IFN-I-dependent manner, as a novel potential adjuvant in anticancer immunotherapy. Here, we report that Poly6 exerts an anti-SARS-CoV-2 effect, with an estimated 50% inhibitory concentration of 2.617 \u00b5M, in the human bronchial epithelial cell line, Calu-3 but not in Vero-E6 cells, which are deficient in type 1 interferon (IFN-I) signaling. We proved via assays based on mRNA profiles, inhibitors, or blocking antibodies that Poly6 can exert an anti-SARS-CoV-2 effect in an IFN-I-dependent manner. We also found that Poly6 inhibits IL-6 production enhanced by SARS-CoV-2 in infected Calu-3 cells at both the transcription and the translation levels, mediated via IL-10 induction in an IFN-I-dependent manner. These results indicate the feasibility of Poly6 as an IFN-I-inducing COVID-19 drug with potent antiviral and anti-inflammatory activities.<\/jats:p>","DOI":"10.3390\/v13071227","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T04:46:57Z","timestamp":1624596417000},"page":"1227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner"],"prefix":"10.3390","volume":"13","author":[{"given":"Yu-Min","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, Korea"},{"name":"Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-7091","authenticated-orcid":false,"given":"Hyein","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, Korea"},{"name":"Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uni","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, Korea"},{"name":"Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-6397","authenticated-orcid":false,"given":"Nam-Hyuk","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, Korea"},{"name":"Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-6709","authenticated-orcid":false,"given":"Bum-Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 110799, Korea"},{"name":"Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Korea"},{"name":"Liver Research Institute, College of Medicine, Seoul National University, Seoul 03080, Korea"},{"name":"Cancer Research Institute, College of Medicine, Seoul National University, Seoul 03080, Korea"},{"name":"Seoul National University Medical Research Center (SNUMRC), Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hu, B., Guo, H., Zhou, P., and Shi, Z.L. (2020). Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol.","DOI":"10.1038\/s41579-020-00459-7"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19","volume":"181","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and Distinct Functions of Type I and Type III Interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"a032003","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ribero, M.S., Jouvenet, N., Dreux, M., and Nisole, S. (2020). Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathogens, 16.","DOI":"10.1371\/journal.ppat.1008737"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e01061-20","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon \u03b2-1a in treatment of severe COVID-19","volume":"64","author":"Rahmani","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","article-title":"Type I IFN immunoprofiling in COVID-19 patients","volume":"146","author":"Viel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17703-6","article-title":"Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion","volume":"11","author":"Simon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kim, H., Lee, S.-A., Kim, D.-W., Lee, S.-H., and Kim, B.-J. (2013). Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054486"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/jmv.21208","article-title":"The prevalence of hepatitis B virus preS deletions occurring naturally in Korean patients infected chronically with genotype C","volume":"80","author":"Mun","year":"2008","journal-title":"J. Med. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.3748\/wjg.v21.i16.5039","article-title":"Hepatitis B virus preS1 deletion is related to viral replication increase and disease progression","volume":"21","author":"Lee","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.bbrc.2018.05.033","article-title":"HBV polymerase-derived peptide exerts an anti-HIV-1 effect by inhibiting the acetylation of viral integrase","volume":"501","author":"Kim","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yang, S.-B., Lee, M.-H., Kim, B.-R., Choi, Y.-M., and Kim, B.-J. (2021). A Hepatitis B Virus-Derived Peptide Exerts an Anticancer Effect via TNF\/iNOS-producing Dendritic Cells in Tumor-Bearing Mouse Model. Cancers, 13.","DOI":"10.3390\/cancers13030407"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","article-title":"Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2","volume":"585","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41588-020-00731-9","article-title":"Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor","volume":"52","author":"Onabajo","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine storm in COVID-19: The current evidence and treatment strategies","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure","volume":"27","author":"Netea","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., and Beziat, V. (2020). Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 370.","DOI":"10.1126\/science.abd4585"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1111\/bph.15206","article-title":"Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19","volume":"177","author":"Robb","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"pe70","DOI":"10.1126\/stke.4162007pe70","article-title":"Type I interferons as anti-inflammatory mediators","volume":"2007","author":"Benveniste","year":"2007","journal-title":"Sci. STKE"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.antiviral.2006.03.006","article-title":"Anti-inflammatory properties of Type I interferons","volume":"71","author":"Billiau","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.imbio.2007.09.011","article-title":"Molecular mechanisms of the anti-inflammatory functions of interferons","volume":"212","author":"Kovarik","year":"2008","journal-title":"Immunobiology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Veeranki, S., Duan, X., Panchanathan, R., Liu, H., and Choubey, D. (2011). IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027040"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1189\/jlb.3HI0914-453R","article-title":"Differential effects of IFN-\u03b2 on IL-12, IL-23, and IL-10 expression in TLR-stimulated dendritic cells","volume":"98","author":"Yen","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tu, Y.F., Chien, C.S., Yarmishyn, A.A., Lin, Y.Y., Luo, Y.H., Lin, Y.T., Lai, W.Y., Yang, D.M., Chou, S.J., and Yang, Y.P. (2020). A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072657"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cytogfr.2020.07.010","article-title":"Are we fully exploiting type I Interferons in today\u2019s fight against COVID-19 pandemic?","volume":"54","author":"Bracci","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106903","DOI":"10.1016\/j.intimp.2020.106903","article-title":"Interferon \u03b2-1b in treatment of severe COVID-19: A randomized clinical trial","volume":"88","author":"Rahmani","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2016.01.001","article-title":"Type I interferons in viral control and immune regulation","volume":"16","author":"Teijaro","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e01410-20","DOI":"10.1128\/JVI.01410-20","article-title":"Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV","volume":"94","author":"Lokugamage","year":"2020","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III Interferons\u2013Induction, Signaling, Evasion, and Application to Combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0149-2918(97)80042-2","article-title":"Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis","volume":"19","author":"Munschauer","year":"1997","journal-title":"Clin. Ther."},{"key":"ref_42","first-page":"29","article-title":"IFN-induced depression: A role for NSAIDs","volume":"37","author":"Asnis","year":"2003","journal-title":"Psychopharmacol. Bull."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5606\/ArchRheumatol.2019.7249","article-title":"Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report","volume":"34","author":"Ozturk","year":"2019","journal-title":"Arch Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The Use of Interferon \u03b1 in Beh\u00e7et Disease: Review of the Literature","volume":"Volume 33","author":"Zierhut","year":"2004","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:23:48Z","timestamp":1760163828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["v13071227"],"URL":"https:\/\/doi.org\/10.3390\/v13071227","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}